Kanser Araştırmalarında Proteomiks Tekniklerin Kullanımı
Özet
Proteomik teknolojiler, proteinlerin sistematik analizi yoluyla kanserin erken teşhisi ve kişiselleştirilmiş tedavi yöntemlerinin geliştirilmesinde kritik bir rol oynamaktadır. Kan plazması, vücuttaki çeşitli dokuların durumunu yansıtan dinamik yapısı ve kolay elde edilebilirliği sayesinde biyobelirteç keşfi için en uygun materyal olarak kabul edilmektedir. Örneklerin saflaştırılması ve analizi için kromatografik yöntemler ile kütle spektrometrisi (MS) tabanlı teknikler bir arada kullanılarak plazmadaki düşük yoğunluklu proteinlerin tespiti sağlanmaktadır. Bu ileri yaklaşımlar; prostat, karaciğer, akciğer ve pankreas gibi pek çok kanser türünde tanısal değeri yüksek spesifik proteinlerin tanımlanmasına imkan tanımaktadır.
Proteomic technologies play a critical role in the early diagnosis of cancer and the development of personalized treatment methods through the systematic analysis of proteins. Blood plasma is considered the most suitable material for biomarker discovery due to its easy accessibility and dynamic structure that reflects the status of various tissues in the body. To ensure the detection of low-abundance proteins in plasma, chromatographic purification methods and mass spectrometry (MS)-based techniques are used in combination. These advanced approaches enable the identification of specific proteins with high diagnostic value in many cancer types, including prostate, liver, lung, and pancreatic cancers.
Referanslar
Liotta, L. A., Ferrari, M., Petricoin, E., Clinical proteomics: written in blood. Nature 2003, 425, 905.
Hanash, S. M., Pitteri, S. J., Faca, V. M., Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571– 579.
Inal, J. M., Kosgodage, U., Azam, S., Stratton, D. et al., Blood/plasma secretome and microvesicles. Biochim. Biophys. Acta 2013, 1834, 2317–2325
Issaq, H. J., Xiao, Z., Veenstra, T. D., Serum and plasma proteomics. Chem. Rev. 2007, 107, 3601–3620.
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M. et al., Plasma proteome profiling to assess human health and disease. Cell Syst. 2016, 2, 185–195
van Waarde, A., Rybczynska, A. A., Ramakrishnan, N. K., Ishiwata, K. et al., Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim. Biophys. Acta 2015, 1848, 2703–2714.
Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J., Zumla, A., Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 2011, 11, 343–354.
Huang, C. H., Chiou, S. H., Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases. World J. Gastroenterol. 2014, 20, 1529– 1536.
Karve, T. M., Cheema, A. K., Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease. J. Amino Acids 2011, 2011, 207691.
Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845–867.
Carrette, O., Burkhard, P. R., Sanchez, J. C., Hochstrasser, D. F., State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat. Protoc. 2006, 1, 812– 823.
Nice, E. C., Rothacker, J., Weinstock, J., Lim, L., Catimel, B., Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis. J. Chromatogr. A 2007, 1168, 190– 210; discussion 189.
Stellwagen, E., Dye affinity chromatography. Curr. Protoc. Protein Sci. 2001, Chapter 9, Unit 9.2.
Andac, M., Cibacron blue immobilized poly (glycidylmethacrylate) nanobeads for albumin removal in proteome studies. Artif.l Cells Nanomed. Biotechnol. 2015, 43, 133– 139.
Odabasi, M., Magnetic dye-affinity beads for human serum albumin purification. Prep. Biochem. Biotechnol. 2011, 41, 287–304.
Altintas, E. B., Denizli, A., Efficient removal of albumin from human serum by monosize dye-affinity beads. J. Chromatogr. B 2006, 832, 216–223.
Pompon, D., Guiard, B., Lederer, F., Binding of Cibacron blue F3GA to the flavin and NADH sites in cytochrome b5 reductase. Eur. J. Biochem. 1980, 110, 565– 570.
Prestera, T., Prochaska, H. J., Talalay, P., Inhibition of NAD(P)H:(quinone-acceptor) oxidoreductase by cibacron blue and related anthraquinone dyes: a structure-activity study. Biochemistry 1992, 31, 824–833.
Arnold, F. H., Haymore, B. L., Engineered metal-binding proteins: purification to protein folding. Science 1991, 252, 1796–1797.
Block, H., Maertens, B., Spriestersbach, A., Brinker, N. et al., Immobilized-metal affinity chromatography (IMAC): a review. Methods Enzymol 2009, 463, 439–473.
Wang, F., Chmil, C., Pierce, F., Ganapathy, K. et al., Immobilized metal affinity chromatography and human serum proteomics. J. Chromatogr. B 2013, 934, 26–33.
Richardson, M. A., Gerlitz, B., Grinnell, B. W., Enhancing protein C interaction with thrombin results in a clotactivated anticoagulant. Nature 1992, 360, 261–264.
Feffer, S. E., Carmosino, L. S., Fox, R. L., Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989, 63, 1303–1307.
Denizli, A., Alkan, M., Garipcan, B., Ozkara, S., Piskin, E., Novel metal-chelate affinity adsorbent for purification of immunoglobulin-G from human plasma. J. Chromatogr. B 2003, 795, 93–103.
Hari, P. R., Paul, W., Sharma, C. P., Adsorption of human IgG on Cu (2+)-immobilized cellulose affinity membrane: preliminary study. J. Biomed. Mater. Res. 2000, 50, 110– 113.
Xu, G., Paige, J. S., Jaffrey, S. R., Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat. Biotechnol. 2010, 28, 868–873.
Haudenschild, D. R., Eldridge, A., Lein, P. J., Chromy, B. A., High abundant protein removal from rodent blood for biomarker discovery. Biochem. Biophys. Res. Commun. 2014, 455, 84–89.
Huang, L., Harvie, G., Feitelson, J. S., Gramatikoff, K. et al., Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005, 5, 3314– 3328.
Zolotarjova, N., Martosella, J., Nicol, G., Bailey, J. et al., Differences among techniques for high-abundant protein depletion. Proteomics 2005, 5, 3304–3313.
Tan, S. H., Mohamedali, A., Kapur, A., Baker, M. S., Ultradepletion of human plasma using chicken antibodies: a proof of concept study. J. Proteome Res. 2013, 12, 2399–2413.
Zhou, M., Lucas, D. A., Chan, K. C., Issaq, H. J. et al., An investigation into the human serum “interactome”. Electrophoresis 2004, 25, 1289–1298.
Lee, H. J., Lee, E. Y., Kwon, M. S., Paik, Y. K., Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 2006, 10, 42–49.
Lesur, A., Ancheva, L., Kim, Y. J., Berchem, G. et al., Screening protein isoforms predictive for cancer using immunoaffinity capture and fast LC-MS in PRM mode. Proteomics Clin. Appl. 2015, 9, 695–705.
Karisch, R., Fernandez, M., Taylor, P., Virtanen, C. et al., Global proteomic assessment of the classical proteintyrosine phosphatome and “Redoxome”. Cell 2011, 146, 826–840.
Anderson, L., Hunter, C. L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573–588.
Wu, C., Duan, J., Liu, T., Smith, R. D., Qian, W. J., Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids. J. Chromatogr. B 2016, 1021, 57–68.
Layton, D., Laverty, C., Nice, E. C., Design and operation of an automated high-throughput monoclonal antibody facility. Biophys. Rev. 2012, 5, 47–55.
Pacholarz, K. J., Garlish, R. A., Taylor, R. J., Barran, P. E., Mass spectrometry based tools to investigate proteinligand interactions for drug discovery. Chem. Soc. Rev. 2012, 41, 4335–4355.
Bensimon, A., Heck, A. J., Aebersold, R., Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 2012, 81, 379–405.
Ahrens, C. H., Brunner, E., Qeli, E., Basler, K., Aebersold, R., Generating and navigating proteome maps using mass spectrometry. Nat. Rev. Mol. Cell Biol. 2010, 11, 789–801.
Guo, X., Hao, Y., Kamilijiang, M., Hasimu, A. et al., Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and ingenuity pathway analysis. Tumour Biol. 2015, 36, 1711–1720.
Brauer, H. A., Lampe, P. D., Yasui, Y. Y., Hamajima, N., Stolowitz, M. L., Biochips that sequentially capture and focus antigens for immunoaffinity MALDI-TOF MS: a new tool for biomarker verification. Proteomics 2010, 10, 3922– 3927.
Longuespee, R., Casadonte, R., Kriegsmann, M., Pottier, C. et al., MALDI mass spectrometry imaging: a cuttingedge tool for fundamental and clinical histopathology. Proteomics Clin. Appl. 2016, 10, 701–719.
Soltwisch, J., Kettling, H., Vens-Cappell, S., Wiegelmann, M. et al., Mass spectrometry imaging with laser-induced postionization. Science 2015, 348, 211–215.
Lou, S., Balluff, B., de Graaff, M. A., Cleven, A. H. et al., Highgrade sarcoma diagnosis and prognosis: biomarker discovery by mass spectrometry imaging. Proteomics 2016, 16, 1802–1813.
Van de Ven, S. M., Bemis, K. D., Lau, K., Adusumilli, R. et al., Protein biomarkers on tissue as imaged via MALDI mass spectrometry: a systematic approach to study the limits of detection. Proteomics 2016, 16, 1660–1669.
Na, C. H., Hong, J. H., Kim, W. S., Shanta, S. R. et al., Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry. Mol. Cells 2015, 38, 624–629.
Goto, T., Terada, N., Inoue, T., Nakayama, K. et al., The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PloS One 2014, 9, e90242.
Frank, R., Hargreaves, R., Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2, 566–580.
Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature. 2003, 422, 198–207.
Gundry, R. L., White, M. Y., Murray, C. I., Kane, L. A. et al., Preparation of proteins and peptides for mass spectrometry analysis in a bottom-up proteomics workflow. Curr. Protoc. Mol. Biol. 2009, Chapter 10, Unit 10.25
Engwegen, J. Y., Gast, M. C., Schellens, J. H., Beijnen, J. H., Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 2006, 27, 251–259.
Hung, K. E., Yu, K. H., Proteomic approaches to cancer biomarkers. Gastroenterology. 2010, 138, 46–51 e41.
Mateo, J., Carreira, S., Sandhu, S., Miranda, S. et al., DNA repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 2015, 373, 1697–1708.
Gann, P. H., Hennekens, C. H., Stampfer, M. J., A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995, 273, 289–294.
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R. et al., Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412, 822–826.
Rantalainen, M., Cloarec, O., Beckonert, O., Wilson, I. D. et al., Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J. Proteome Res. 2006, 5, 2642–2655.
Nazarian, A., Lawlor, K., Yi, S. S., Philip, J. et al., Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol. Cell. Proteomics. 2014, 13, 3082–3096.
Kalin, M., Cima, I., Schiess, R., Fankhauser, N. et al., Novel prognostic markers in the serum of patients with castrationresistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur. Urol. 2011, 60, 1235–1243.
Poon, T. C., Sung, J. J., Chow, S. M., Ng, E. K. et al., Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology. 2006, 130, 1858–1864.
Kudo, M., Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015, 4, 39–50.
Sato, Y., Nakata, K., Kato, Y., Shima, M. et al., Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 1993, 328, 1802–1806.
Shang, S., Plymoth, A., Ge, S., Feng, Z. et al., Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55, 483–490.
Ahn, Y. H., Shin, P. M., Oh, N. R., Park, G. W. et al., A lectincoupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J. Proteomics 2012, 75, 5507– 5515.
Ferrin, G., Ranchal, I., Llamoza, C., Rodriguez-Peralvarez, M. L. et al., Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. Liver Int. 2014, 34, 438–446.
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N. et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 2018–2028.
Leighl, N. B., Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr. Oncol. 2012, 19, S52–S58.
Guergova-Kuras, M., Kurucz, I., Hempel, W., Tardieu, N. et al., Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol. Cell. Proteomics 2011, 10, M111.010298.
Cheng, Z. Z., Corey, M. J., Parepalo, M., Majno, S. et al., Complement factor H as a marker for detection of bladder cancer. Clin. Chem. 2005, 51, 856–863.
Yu, K. H., Rustgi, A. K., Blair, I. A., Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 2005, 4, 1742–1751.
Tan, F., Jiang, Y., Sun, N., Chen, Z. et al., Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol. Cell. Proteomics. 2012, 11, M111.008821.
Seton-Rogers, S., Pancreatic cancer: a matter of timing. Nat. Rev. Cancer. 2015, 15, 256–257.
Chen, R., Pan, S., Brentnall, T. A., Aebersold, R., Proteomic profiling of pancreatic cancer for biomarker discovery. Mol. Cell. Proteomics 2005, 4, 523–533.
Kakisaka, T., Kondo, T., Okano, T., Fujii, K. et al., Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B 2007, 852, 257–267.
Faca, V. M., Song, K. S., Wang, H., Zhang, Q. et al., A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008, 5, e123.
Saldanha, R. G., Molloy, M. P., Bdeir, K., Cines, D. B. et al., Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J. Proteome Res. 2007, 6, 1016–1028.
